Valneva’s C difficile Vaccine Candidate Reported Positive Phase II Results

Racing against big-name vaccines players, Valneva reported positive Phase II results this week for its GlaxoSmithKline-partnered C. difficile vaccine candidate, saying the shot proved to be “highly immunogenic” while also offering a good safety and a tolerable profile.

The trial, conducted in Germany and the United States, tested the vaccine candidate in 500 volunteers separated into two age groups: 50 to 64 and 65 and above. Researchers reported that the vaccine was immunogenic at all doses and formulations tested, with a high-dose formulation containing no adjuvant generating a superior response.

With the results, the Lyon, France-headquartered company said it’ll announce further development steps after its final Phase II closeout in Q2 2016.

To read this article in its entirety click on the link below:

http://www.fiercevaccines.com/story/valnevas-c-diff-vaccine-found-be-highly-immunogenic-phii/2015-12-01

 

*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.